Scientific Program

Conference Series Ltd invites all the participants across the globe to attend World Haematology and Medical Oncology Conference Osaka, Japan.

Day 1 :

Keynote Forum

Ryan Robetorye,

Mayo Clinic, USA

Keynote: Acute myeloid leukemia with characteristic molecular mutations

Time : 09:20-10:20

OMICS International Medical Oncology-2018 International Conference Keynote Speaker Ryan Robetorye, photo
Biography:

Ryan S Robetorye has received his MD and PhD degrees from Baylor College of Medicine in Houston, Texas. He is board certified in Clinical Pathology, Hematology and Molecular Genetic Pathology and currently works as a Consultant at the Mayo Clinic in Phoenix, Arizona. He currently serves as the Medical Director of several clinical laboratories at the Mayo Clinic.

 

Abstract:

Cytogenetic studies have traditionally played one of the most important roles for the classification and risk stratification of acute myeloid leukemia (AML). AML patients with a favorable risk cytogenetic profile are associated with relatively good responses to chemotherapy-based regimens and high complete remission rates. AML patients with unfavorable cytogenetic risk profiles require allogeneic stem cell transplantation to improve prognosis. However, most AML cases have an intermediate prognosis and include approximately 50% of AML cases that have a normal karyotype at diagnosis and cannot be further sub-classified based on cytogenetics. In recent years, several recurrent molecular mutations discovered in AML have been proposed to establish better classification of prognosis in the intermediate cytogenetic risk category. Recent revisions in the WHO- ‘Classification of tumors of hematopoietic and lymphoid tissues’ have resulted in adopting the provisional diagnostic entities- ‘AML with mutated CEBPA’ and ‘AML with mutated NPM1’ as distinct entities and adding ‘AML with mutated RUNX1’ as a provisional diagnostic entity. This presentation will focus on the characteristic clinicopathologic features of AML with mutations in the CEBPA, NPM1 and RUNX1 genes.

 

OMICS International Medical Oncology-2018 International Conference Keynote Speaker Gi- Ming Lai, photo
Biography:

Gi-Ming Lai has an expertise in clinical trial and his research interest is to look for more efficacious cancer therapy by combining drugs or seeking active ingredients of natural products from which are regarding as complementary and alternative medicine.

 

Abstract:

Malignant glioma (MG) is a poor prognosis disease because of inevitable recurrence after operation, radiotherapy and chemotherapy. Searching a more effective treatment modality is urgently needed. Our previous studies have shown the activities of natural products against MG stem cells. It is interesting to further elucidate the underlying molecular mechanisms. Epigenetic modification has been proposed to be a potential novel anticancer strategy and could lead to differentiation induction of cancer cells. We thus explore the effects of market available natural products such as Oligo-Fucoidan (OF) and human urine extract (CDA-2) on this paradigm in the MG cell lines including Grade III MG cells (U87MG) and Grade IV MG cells (GBM8401, DBTRG) and compared to immortalized astrocyte cell line SVGp12. The results show that both OF and CDA-2 markedly suppresses the proliferation of MG cells and only slightly affects that of SVGp12 cells. CDA-2 inhibits the mRNA expression of DNA methyltransferases (DNMTs) accompanied with mRNA induction of neuronal marker MAP2 (microtubule associated protein 2) and astrocyte marker GFAP (glial fibrillary acidic protein). In addition to DNMTs inhibition and GFAP induction, OF also increases the mRNA expression of histone acetyltransferase CRBBP along with drastic induction of oligodendrocyte marker MBP (myelin basic protein) in U87MG cells. Interestingly, combining with synthetic demethylating agent decitabine further synergizes the OF-induced MBP in U87MG cells, while combining with histone deacetylase inhibitor Chidamide significantly augments the OF-induced MAP2 and NeuN in GBM8401 cells. Taken together, CDA-2 and OF could substantially modulate genes critical for epigenetic regulation (DNA methylation and histone acetylation) during induction of various differentiation markers, suggesting the potential for their clinical application. Further clinical trial to evaluate their efficacy in recurrent MG patients is warranted.